ISPOR recommends disclaimer for pharmacoeconomic models Newsletter Article 13 February 2013 Pages: 2 - 2
Cost-consequence analyses useful to healthcare decision-makers Newsletter Article 13 February 2013 Pages: 2 - 2
A method to the madness in the treatment of asthma Eugene Sorkin Newsletter Article 13 February 2013 Pages: 3 - 5
MCOs well suited to conduct large cost-effectiveness trials Newsletter Article 13 February 2013 Pages: 6 - 6
Why do children with URTIs still receive antibacterials? Newsletter Article 13 February 2013 Pages: 7 - 7
Drug use concomitant with cyclosporin after renal transplant Newsletter Article 13 February 2013 Pages: 7 - 7
Use filgrastim after stem cell transplant in lymphatic cancer Newsletter Article 13 February 2013 Pages: 8 - 8
Cefixime stepdown therapy cost saving in Canadian hospital Newsletter Article 13 February 2013 Pages: 8 - 8
Patients report improvements with asthma DM programme Newsletter Article 13 February 2013 Pages: 9 - 9
Appropriate care underused in Medicare patients with acute MI Newsletter Article 13 February 2013 Pages: 9 - 9
Method of physician compensation does not affect healthcare costs Newsletter Article 13 February 2013 Pages: 10 - 10
Early lisinopril use is cost effective in acute MI Newsletter Article 13 February 2013 Pages: 11 - 11
Large resource and cost savings for CHF and asthma programmes Newsletter Article 13 February 2013 Pages: 12 - 12
Restricting access to neonatal ICUs is ill-advised Newsletter Article 13 February 2013 Pages: 13 - 13
Naftidrofuryl improves QOL in intermittent claudication Newsletter Article 13 February 2013 Pages: 13 - 13
Salmeterol improves QOL in asthma not well-controlled by steroids Newsletter Article 13 February 2013 Pages: 14 - 14
Patient education a low-cost approach to chronic pain Newsletter Article 13 February 2013 Pages: 14 - 14
Cost reduction or care management the priority for the future? Newsletter Article 13 February 2013 Pages: 15 - 15
